NCT07202845Recruiting
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Source: ClinicalTrials.gov · Last updated 2 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 39 (estimated)
- First submitted
- 24 Sept 2025
- Start date
- 29 Aug 2025
- Primary completion date
- 1 May 2026
- Lead sponsor
- Assiut University
- Diseases
- Bladder cancer
- NCT number
- NCT07202845
What you commit to
- Study type: Observational
- Planned participants: 39
- From 29 Aug 2025 to the primary completion date, 1 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received pelvic radiotherapy.
- Previous open or laparoscopic pelvic surgery.
Other illness
- Severe renal impairment
Other
- Presence of distant metastases at diagnosis.
- Patients with contraindications to MRI.
- Ineligibility to cisplatin
Who the study is looking for
- Patients diagnosed with cT2-T4 urothelial carcinoma of the urinary bladder, according to the TNM classification (8), who give informed, written consent on participation in the study and approve all its requirements.
- Planned to receive cisplatin-based NAC followed by radical cystectomy.
- Willing to undergo three mpMRI scans (baseline, 24h post-initial cisplatin, and post-NAC).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amr E. Darwish Coordinator of this site? Confirm its status | Asyut | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.